Evaluation in 47 213 neonates of a strategy for neonatal screening of cystic fibrosis coupling pancreatitis-associated protein and immunoreactive trypsinogen assays;Évaluation sur 47 213 enfants d'une stratégie de dépistage néonatal de la mucoviscidose associant les dosages de pancreatitis-associated protein et de trypsinogène immunoréactive

Archives de Pediatrie

Volumn 8, Issue 3, 2001, Pages 275-281

  Barthellemy, S ^a   Maurin, N ^b   Roussey, M ^c   Ferec C ^d   Murolo, S ^a   Berthezene P ^a   Iovanna, J L ^a   Dagorn, J C ^a   Sarles, J ^b  

^a INSERM   (France)

^b Timone Enfant Hospital   (France)

^c SERVICE DE RHUMATOLOGIE   (France)

^d Laboratoire de Genetique Moleculaire   (France)

Author keywords

Cystic fibrosis; Neonatal screening

Indexed keywords

PANCREATITIS ASSOCIATED PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; TRYPSINOGEN; ACUTE PHASE PROTEIN; CFTR PROTEIN, HUMAN; LECTIN; PANCREATITIS-ASSOCIATED PROTEIN; TUMOR ANTIGEN; TUMOR MARKER;

ARTICLE; CYSTIC FIBROSIS; FRANCE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; PHENOTYPE; PROTEIN BLOOD LEVEL; SWEAT TEST; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEASIBILITY STUDY; GENETIC SCREENING; GENETICS; HEALTH CARE QUALITY; METABOLISM; METHODOLOGY; MUTATION; PATIENT SELECTION; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARD;

ACUTE-PHASE PROTEINS; ANTIGENS, NEOPLASM; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FRANCE; GENETIC SCREENING; HUMANS; INFANT, NEWBORN; LECTINS, C-TYPE; MUTATION; NEONATAL SCREENING; PATIENT SELECTION; PROGRAM EVALUATION; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TRYPSINOGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 18544400304     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(00)00194-9     Document Type: Article

References (12)

1. Principles and practice of mass screening for disease
2. Nutritional benefits of neonatal screening for cystic fibrosis
3. Neonatal screening for cystic fibrosis: A comparison of two strategies for case detection in 1.2 million babies
4. Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis: Comparison of screening protocols
5. Neonatal screening for cystic fibrosis: Result of a pilot study using both immunoreactive trypsinogen and cystic fibrosis gene mutation analyses
6. Blood concentrations of pancreatitis associated protein in neonates: Relevance to neonatal screening for cystic fibrosis
7. Sweat testing for the diagnosis of cystic fibrosis: Practical considerations
8. Identification of 12 novel mutations in the CFTR gene
9. Serum levels of pancreatitis-associated protein as indicators of the course of acute pancreatitis
10. Prenatal diagnosis in 200 pregnancies with a 1-in-4 risk of cystic fibrosis
11. Dried-blood spot screening for cystic fibrosis in the newborn